Comparative Pharmacology
Head-to-head clinical analysis: AUKELSO versus EXELDERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUKELSO versus EXELDERM.
AUKELSO vs EXELDERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, specifically the mTORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
400 mg orally twice daily with food.
Apply a thin layer to affected skin twice daily (morning and evening).
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Category C
Category C
Topical Antifungal
Topical Antifungal